Marker Therapeutics, Inc. Cash Flow Statement
MRKR|3 years of annual SEC 10-K data (FY2018-FY2021)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Marker Therapeutics, Inc. used $27M in operating cash flow in FY2021.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2019 | FY2018 |
|---|---|---|---|
| Net Income | -$41.9M | -$21.4M | -$11.0M |
| Depreciation & Amortization | $2.1M | $105.1K | - |
| Operating Cash Flow | -$27.3M | -$18.3M | -$8.4M |
| Capital Expenditures | - | $375.0K | $0 |
| Free Cash Flow | - | -$18.7M | -$8.4M |
| Share Buybacks | - | - | $310.5K |
| FCF Margin | - | -8752.3% | -4610.1% |